Use of Mass Spectrometry Help Improve TTP Patient Outcomes
News Jan 19, 2007
In an article in the current issue of Spectroscopy, researchers at the Ohio State University College of Medicine and Public Health describe the clinical evaluation of thrombotic thrombocytopenic purpura (TTP) using Surface Enhanced Laser Desorption/Ionization Time of Flight (SELDI-TOF) mass spectrometry.
TTP is a condition caused by a deficiency in a metalloproteinase called ADAMTS13. With a timely diagnosis, TTP patients usually respond to plasma exchange therapy. However, many patients relapse after therapy. Thus, there is a need for both a rapid diagnostic test to help clinicians start therapy and for a biomarker that can anticipate recurrence.
Without enough ADAMTS13, extensive blood clots may occur throughout the body and can cause death. ADAMTS13 prevents this by breaking apart another protein that causes the clotting process. By measuring one of the broken fragments using SELDI-TOF, the researchers found that they could determine ADAMTS13 activity levels in the patient’s blood.
SELDI-TOF mass spectrometry can offer a property to capture and concentrate the target protein in a binding array. Afterwards it can become simple to measure the analyte.
Writing in the article, Haifeng M. Wu, MD, states “Since the implementation of our SELDI-TOF based method, fast turnaround time for the detection of ADAMTS13 activity has greatly helped us in making the correct diagnosis, instituting appropriate therapy, and improving patient outcomes.”
The article is “Application of SELDI-TOF mass spectrometry in clinical evaluation of thrombotic thrombocytopenic purpura” by Haifeng M. Wu, Spero R. Cataland, Michael Bissell and Ming Jin. It appears in Spectroscopy, Volume 20, Issue 5/6 (2007), published by IOS Press.
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019